General Information of Drug Combination (ID: DCNCFP6)

Drug Combination Name
Voriconazole Ibrexafungerp
Indication
Disease Entry Status REF
Invasive Pulmonary Aspergillosis Phase 2 [1]
Component Drugs Voriconazole   DMAOL2S Ibrexafungerp   DMK1IPV
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL is unavailable

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Voriconazole
Disease Entry ICD 11 Status REF
Aspergillosis 1F20 Approved [2]
Candidiasis 1F23 Approved [2]
Fusariosis N.A. Approved [2]
Invasive aspergillosis 1F20.0 Approved [3]
Invasive candidiasis 1F23 Approved [2]
Neuroaspergillosis N.A. Approved [2]
Candidemia 1F23.3Y Investigative [2]
Esophageal candidiasis N.A. Investigative [2]
Voriconazole Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Candida Cytochrome P450 51 (Candi ERG11) TTTSOUD CP51_CANAL Modulator [7]
------------------------------------------------------------------------------------
Voriconazole Interacts with 4 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [8]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Metabolism [9]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Metabolism [9]
Prostaglandin G/H synthase 1 (COX-1) DE073H6 PGH1_HUMAN Metabolism [10]
------------------------------------------------------------------------------------
Voriconazole Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytochrome P450 2C19 (CYP2C19) OTFMJYYE CP2CJ_HUMAN Decreases Activity [11]
------------------------------------------------------------------------------------
Indication(s) of Ibrexafungerp
Disease Entry ICD 11 Status REF
Vulvovaginal Candidiasis 1F23.10 Approved [4]
Invasive candidiasis 1F23 Phase 3 [5]
Fungal infection 1F29-1F2F Phase 2 [6]
Ibrexafungerp Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Fungal 1,3-beta-glucan synthase (Fung GSC2) TT0SFXH FKS2_YEAST Inhibitor [12]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT03672292) Study to Evaluate the Safety and Efficacy of the Coadministration of Ibrexafungerp (SCY-078) With Voriconazole in Patients With Invasive Pulmonary Aspergillosis
2 Voriconazole FDA Label
3 Disk diffusion test and E-test with enriched Mueller-Hinton agar for determining susceptibility of Candida species to voriconazole and fluconazole. J Microbiol Immunol Infect. 2009 Apr;42(2):148-53.
4 FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 214900.
5 ClinicalTrials.gov (NCT03059992) Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment (FURI). U.S. National Institutes of Health.
6 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031918)
7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
8 Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes. Biochem Pharmacol. 2007 Jun 15;73(12):2020-6.
9 Effect of voriconazole on the pharmacokinetics of diclofenac. Fundam Clin Pharmacol. 2007 Dec;21(6):651-6.
10 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
11 The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis. Antimicrob Agents Chemother. 2004 Sep;48(9):3272-8.
12 Pharmacodynamic target evaluation of a novel oral glucan synthase inhibitor, SCY-078 (MK-3118), using an in vivo murine invasive candidiasis model. Antimicrob Agents Chemother. 2015 Feb;59(2):1265-72.